Pre-Treatment Status and Changes in Autoantibodies, Lymphocytic Populations, Cytokines and VEGF during Sunitinib Treatment of Metastatic Renal Cell Carcinoma (mRCC)
Alexandra Karadimou1*, Nikos Gavalas1, Marinos Tsiatas1, Eleni Sereti2, Paraskevi-Sofia Trachana1, Maria Spyropoulou-Vlachou2, Eleni Karga3, Evangelos Terpos1, Ourania Tsitsilonis4, Meletios A. Dimopoulos1 and Aristotelis Bamias1
- *Corresponding Author:
- Alexandra Karadimou MD
1 Nikou Rizou str, 18547
Neo Faliro, Piraeus, Greece
E-mail: [email protected]
Received Date: January 14, 2014; Accepted Date: January 29, 2014; Published Date: January 31, 2014
Citation: Karadimou A, Gavalas N, Tsiatas M, Sereti E, Trachana PS et al., (2014) Pre-Treatment Status and Changes in Autoantibodies, Lymphocytic Populations, Cytokines and VEGF during Sunitinib Treatment of Metastatic Renal Cell Carcinoma (mRCC). Transl Med 4:124. doi:10.4172/2161-1025.1000124
Copyright: © 2014 Karadimou A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Immunotherapy has been effective in mRCC. Given the improved efficacy of anti-VEGF therapies in mRCC, their effect on the immune system emerges as a reasonable question.
Serum autoantibodies (aAbs), Interferon-γ (IFN-γ), Interleukins (ILs), VEGF and blood lymphocytic populations were determined in 43 previously untreated mRCC patients, before and during sunitinib therapy.
81% of patients had at least 1 baseline aAb. During treatment 83% of patients without baseline aAbs developed aAbs, while C3 and IL-6 levels were increased. All changes were observed the first 9 months of treatment but had no prognostic significance. Baseline low VEGF and IL-6 levels were associated with improved Progression-Free (PFS) and Cancer-Specific (CSS) Survival.
Sunitinib treatment can result in aAbs development but this does not improve prognosis. Baseline VEGF and IL-6 were correlated with outcome.